ThyroSeq® Thyroid Genomic Classifier (GC) is
a molecular test specifically designed to
determine if a thyroid nodule is benign (not
cancer) or malignant (cancer) when cytology
result is indeterminate.
ThyroSeq also provides specific information
about the genetic makeup of the nodule which
allows physicians to determine an
individualized course of treatment.
If a ThyroSeq result is negative, the
patient can likely avoid surgical removal of
their thyroid. If the result is positive,
ThyroSeq provides additional information
that helps the physician select the most
appropriate surgery, which may include
preserving part of the patient’s thyroid,
protecting natural thyroid function.
For nodules with malignant cytology
(Bethesda VI), ThyroSeq can help inform the
extent of surgery and targeted therapy
selection. For benign cytology nodules
(Bethesda II) with clinical suspicion for
malignancy, ThyroSeq may help clarify
diagnosis.
Patient Management Using ThyroSeq
ThyroSeq test results refine cancer probability in
thyroid nodules with indeterminate cytology,
informing the most appropriate management of these
patients.
Comprehensive molecular profiling by ThyroSeq
provides preoperative prognostication of cancerous
nodules, informing the extent of surgery and
therapeutic options
ThyroSeq provides:
Preoperative assessment of the Risk of
Cancer Recurrence (RCR)
Detection of clinically actionable
therapeutic targets
Therapeutic gene targets (variants and
fusions) detectable by ThyroSeq
The ThyroSeq test was designed by expert physicians
in the field of thyroid cancer. The test combines
years of scientific and clinical experience to help
personalize patient care.
The leading platform for comprehensive
genotyping of thyroid nodules
Utilizes a proprietary Genomic
Classifier (GC) that relies on the
algorithmic analysis of all detected
genetic alterations to report the test
result as Positive or Negative
Results include a specific probability
of cancer, potential management, and
risk of recurrence
The ThyroSeq test was designed by expert physicians
in the field of thyroid cancer. The test combines
years of scientific and clinical experience to help
personalize patient care.
ThyroSeq testing is performed on an FNA
biopsy, either freshly collected during an
FNA procedure or on a previously made FNA
cytology smear. Cell block and FFPE surgical
tissue slides are also acceptable for
ThyroSeq testing.
To set up ThyroSeq testing, please fill out
the form. We will get back to you as soon as
possible.
I understand that by checking the Consent
box, I agree to UPMC’s
EU Privacy Notice.
“
Not accepting this ‘surgery to see’ for my
daughter I came to discover ThyroSeq, a
totally non-surgical solution in determining
just what my daughter’s thyroid nodule was
presenting. Following the test and assured
by the most impeccable and flawless
attention to us as clients, we received the
best ever news that my daughter’s nodule was
in fact Negative...the same result that a
Thyroid Surgeon would have found had a
partial Thyroidectomy been needlessly
undertaken. We had prepared for a worse
outcome but even then we were assured that
ThyroSeq’s finding would have guided our own
surgeon to perform a more targeted surgery
if so needed.
To all at UPMC I cannot thank you enough for
this truly impressive and indispensable tool
called ThyroSeq. I urge all those presented
with an indeterminate thyroid nodule result
to not accept this ‘surgery to see’ and
instead have your health ‘secured by
science’ as ThyroSeq has so plainly proven
for my daughter who has been spared the
trauma of this standard surgical practice,
the possibility of being medicated on in to
the future and possible evidence of an
operational scar following needless surgery.
— Father of an international ThyroSeq patient
By using this website, you agree to our
use of cookies. We use cookies to provide you with an
excellent experience, analyze site traffic, and to help our
website run effectively.
Therapeutic gene targets (variants and
fusions) detectable by ThyroSeq
